ImmuCell Corporation (ICCC)

5.02 -0.03 (-0.59%) As of 03:44PM EDT. Market open.

ImmuCell Corporation

56 Evergreen Drive
Portland, ME 04103
United States
207 878 2770
https://immucell.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 74

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Michael F. Brigham	President, CEO, Principal Financial Officer, Treasurer, Secretary & Director	395.24k	N/A	1961
Ms. Bobbi Jo Brockmann	VP of Sales & Marketing and Director	323.52k	N/A	1977
Elizabeth S. Toothaker	Director of Finance & Administration and Controller	N/A	N/A	N/A
Mr. A. Gustavo Scaffa	Senior Director of Quality	N/A	N/A	N/A
John W. Zinckgraf	Director of Product Development	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.

Corporate governance

ImmuCell Corporation’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.